PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Campbell, J.E.* ; Müller, T.D. ; Finan, B.* ; DiMarchi, R.D.* ; Tschöp, M.H. ; D'Alessio, D.A.*

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications.

Cell Metab. 35, 1519-1529 (2023)
Publ. Version/Full Text DOI PMC
Closed
Open Access Green as soon as Postprint is submitted to ZB.
The incretin system is an essential metabolic axis that regulates postprandial metabolism. The two incretin peptides that enable this effect are the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide 1 (GLP-1), which have cognate receptors (GIPR and GLP-1R) on islet β cells as well as in other tissues. Pharmacologic engagement of the GLP-1R is a proven strategy for treating hyperglycemia in diabetes and reducing body weight. Tirzepatide is the first monomeric peptide with dual activity at both incretin receptors now available for clinical use, and in clinical trials it has shown unprecedented effects to reduce blood glucose and body weight. Here, we discuss the foundational science that led to the development of monomeric multi-incretin receptor agonists, culminating in the development of tirzepatide. We also look to the future of this field and comment on how the concept of multi-receptor agonists will continue to progress for the treatment of metabolic disease.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
29.000
0.000
4
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Gip ; Glp-1 ; Diabetes ; Incretin ; Obesity ; Tirzepatide; Glucagon-like Peptide-1; Gastric-inhibitory Polypeptide; Glp-1 Receptor Agonist; Dependent Insulinotropic Polypeptide; Body-weight; Glucose-intolerance; Glycemic Control; Adipose-tissue; Induced Nausea; Double-blind
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 1550-4131
e-ISSN 1932-7420
Journal Cell Metabolism
Quellenangaben Volume: 35, Issue: 9, Pages: 1519-1529 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
POF-Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502200-001
G-501900-221
Grants European Research Council ERC AdG HypoFlam
German Center for Diabetes Research (DZD e.V.)
German Research Foundation (DFG)
European Research Council ERC-CoG Trusted
NIH
DOI 10.1016/j.cmet.2023.07.010
WOS ID 001138180700001
Scopus ID 85169023000
PubMed ID 37591245
Erfassungsdatum 2023-10-06
[➜Report correction]